Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma Holdings (MTNB) reported positive results from the first two cohorts of its EnACT study for MAT2203, an oral treatment for cryptococcal meningitis, prompting the DSMB to recommend progressing in the study. Additionally, the company initiated a Phase 1 study for MAT2501, an oral aminoglycoside antibiotic. Financially, MTNB reported a net loss of $6.8 million for Q3 2021, consistent with the previous year. The company believes it has sufficient cash reserves of $53.8 million to fund operations into 2024. Kathryn Penkus Corzo joined the Board of Directors.
Matinas BioPharma Holdings (MTNB) will host a conference call on November 8, 2021, at 8:30 a.m. ET to discuss its Q3 2021 operational and financial results. To join, call (877) 407-5976 (toll-free) or (412) 902-0031 (toll), using conference ID 13723555. The call will also be webcast on their website, where it will be archived for 90 days. Matinas specializes in a lipid nanocrystal delivery platform for therapeutics, with ongoing studies for drug candidates MAT2203 and MAT2501, targeting fungal and bacterial infections respectively.
Matinas BioPharma Holdings has been selected for the B. Riley Fall 2021 Growth Biotech Best Ideas Series. CEO Jerome D. Jabbour will lead a fireside chat on November 23, 2021, at 12:30 p.m. ET, discussing their innovative lipid nanocrystal platform aimed at effective intracellular drug delivery for serious diseases. The company is advancing multiple product candidates, including MAT2203 for fungal infections and MAT2501 for bacterial infections, both benefiting from unique delivery technology. A viewing option for the chat will be available on their website.
Matinas BioPharma Holdings (NYSE AMER: MTNB) has initiated a Phase 1 study of MAT2501, an oral formulation of amikacin, with the first patient dosed. The trial aims to assess safety, tolerability, and pharmacokinetics, completing enrollment by Q1 2022 and reporting data in Q2 2022. MAT2501 targets nontuberculous mycobacterial infections and marks a significant advancement as a potential first oral aminoglycoside. Supported by a $4.2 million award from the Cystic Fibrosis Foundation, MAT2501 has received FDA designations that could provide up to 12 years of marketing exclusivity if approved.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) announced the nomination of Kathryn Penkus Corzo for election to its Board of Directors at the 2021 Annual Meeting on November 1, 2021. Corzo, a partner at Takeda Ventures and former Head of Oncology Cell Therapy Development at Takeda, brings over 25 years of experience in biopharma. The company also noted that Patrick LePore will not seek re-election. Notable advancements include positive EnACT data for MAT2203, showing 95% survival in HIV patients with cryptococcal meningitis.
Matinas BioPharma (MTNB) presented its company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is available on-demand via their investor website. Matinas focuses on the intracellular delivery of therapeutics using its lipid nanocrystal (LNC) platform. Their lead product, MAT2203, an oral formulation of amphotericin B, shows promising Phase 2 results in HIV patients with cryptococcal meningitis. Additionally, MAT2501 is set to enter Phase 1 trials for treating bacterial infections.
Matinas BioPharma (MTNB) announced positive results from the EnACT trial of MAT2203 for treating cryptococcal meningitis. Early Fungicidal Activity (EFA) reached 0.38 log10 CFU/mL/day, surpassing the target of >0.20, indicating effective fungal clearance. A 95% overall survival rate was observed in Cohort 2 with no breakthrough infections. MAT2203 showed no kidney toxicity or electrolyte issues during 6 weeks of treatment. The Data Safety Monitoring Board supports advancing to Cohort 3, with enrollment underway, and the company plans to seek FDA engagement for early approval.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) announced a Notice of Allowance from the USPTO for its oral formulation MAT2203, an antifungal medicine. This patent, covering a combination of amphotericin B and additional antifungal agents for treating central nervous system infections, extends patent protection to 2037. The company now holds six issued U.S. patents and 25 patents for its lipid nanocrystal platform, enhancing MAT2203's commercial potential. MAT2203 is currently in a Phase 2 clinical trial for cryptococcal meningitis in HIV patients, with further studies expected.
Matinas BioPharma Holdings, Inc. (MTNB) announced the completion of patient enrollment in the second cohort of the EnACT study for MAT2203, targeting cryptococcal meningitis, with data review expected in September 2021. Positive FDA feedback has enabled the initiation of a Phase 1 study for MAT2501, anticipated in Q4 2021. In vitro studies of lipid nanocrystal formulations of remdesivir show enhanced efficacy compared to traditional forms. Financially, cash reserves stood at approximately $59.8 million, providing operational support into 2024, with a reduced net loss of $5 million in Q2 2021.
Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will participate in the BTIG Virtual Biotechnology Conference on August 10, 2021, at 3:00 p.m. ET. The company will also hold investor meetings during this event. Matinas focuses on enhancing drug delivery through its lipid nanocrystal (LNC) technology, which aims to overcome complex delivery challenges for therapeutics. Their lead candidates include MAT2203, an oral antifungal for cryptococcal meningitis, and MAT2501, an oral antibiotic for bacterial infections, both nearing significant clinical milestones.